These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

933 related items for PubMed ID: 31769228

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S, Lee B, Park WY, Choi YL, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH.
    Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
    [Abstract] [Full Text] [Related]

  • 3. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S, Dai L, Wang L, Wang W, Wu D, Wang K, He Z, Wang A, Chen H, Zhang P, Dong X, Dong YA, Wang K, Yao M, Wang M.
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: A retrospective analysis.
    Wang S, Ma P, Ma G, Lv Z, Wu F, Guo M, Li Y, Tan Q, Song S, Zhou E, Geng W, Duan Y, Li Y, Jin Y.
    Eur J Cancer; 2020 Jan; 124():1-14. PubMed ID: 31707279
    [Abstract] [Full Text] [Related]

  • 7. KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung.
    Yokota K, Sasaki H, Okuda K, Shimizu S, Shitara M, Hikosaka Y, Moriyama S, Yano M, Fujii Y.
    Oncol Rep; 2012 Oct; 28(4):1187-92. PubMed ID: 22797671
    [Abstract] [Full Text] [Related]

  • 8. [Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau].
    Lin YP, Li Q, Ma LY, Liu X, Dai M, Wang XX, Li HS, Liu JX, Shen ZH, Guo YJ, Du YX, Yang RJ, Huang YC, Zhou YC.
    Zhonghua Zhong Liu Za Zhi; 2020 Sep 23; 42(9):735-740. PubMed ID: 32988155
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Adverse Events of Concurrent Radiotherapy and ALK Inhibitors for Brain Metastases of ALK-Rearranged Lung Adenocarcinoma.
    Nakashima T, Nonoshita T, Hirata H, Inoue K, Nagashima A, Yoshitake T, Asai K, Shioyama Y.
    In Vivo; 2020 Sep 23; 34(1):247-253. PubMed ID: 31882485
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Driver and novel genes correlated with metastasis of non-small cell lung cancer: A comprehensive analysis.
    Wu Y, Ni H, Yang D, Niu Y, Chen K, Xu J, Wang F, Tang S, Shi Y, Zhang H, Hu J, Xia D, Wu Y.
    Pathol Res Pract; 2021 Aug 23; 224():153551. PubMed ID: 34298439
    [Abstract] [Full Text] [Related]

  • 13. [Clinicopathological features of patients with RET fusion-positive non-small cell lung cancer].
    Tan Q, Ji Y, Wang XL, Wang ZW, Qi XW, Liu YK.
    Zhonghua Bing Li Xue Za Zhi; 2023 Feb 08; 52(2):124-128. PubMed ID: 36748131
    [Abstract] [Full Text] [Related]

  • 14. ALK Mutation Status in EGFR-negative Non-small-cell Lung Cancer Patients in Bulgaria.
    Djambazov SN, Vekov TY, Mekov EV, Slavchev GS, Petkov RE, Kostadinov DT, Konteva LT.
    Folia Med (Plovdiv); 2018 Sep 01; 60(3):397-401. PubMed ID: 30355843
    [Abstract] [Full Text] [Related]

  • 15. Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy.
    Press RH, Zhang C, Cassidy RJ, Ferris MJ, Zhong J, Steuer CE, Pillai RN, Owonikoko TK, Kahn S, Ramalingam SS, Patel PR, Curran WJ, Shu HG, Sica GL, Higgins KA.
    Cancer; 2018 Sep 01; 124(17):3586-3595. PubMed ID: 30120912
    [Abstract] [Full Text] [Related]

  • 16. Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis.
    Zhang S, Yan B, Zheng J, Zhao J, Zhou J.
    Oncotarget; 2016 Sep 27; 7(39):63758-63766. PubMed ID: 27563816
    [Abstract] [Full Text] [Related]

  • 17. PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy.
    Zhu Y, Zhang Y, Hu X, Wang M, Wang H, Liu Y.
    J Cancer Res Clin Oncol; 2022 Dec 27; 148(12):3557-3566. PubMed ID: 35857126
    [Abstract] [Full Text] [Related]

  • 18. Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung: Study in a tertiary care hospital.
    Ghosh M, Mukhopadhyay M, Das C, Chatterjee S, Naskar BG.
    J Cancer Res Ther; 2021 Dec 27; 17(6):1389-1396. PubMed ID: 34916369
    [Abstract] [Full Text] [Related]

  • 19. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
    Ke L, Xu M, Jiang X, Sun X.
    Med Sci Monit; 2018 Dec 23; 24():9364-9369. PubMed ID: 30580372
    [Abstract] [Full Text] [Related]

  • 20. Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma-like carcinoma.
    Yin K, Feng HB, Li LL, Chen Y, Xie Z, Lv ZY, Guo WB, Lu DX, Yang XN, Yan WQ, Wu YL, Zhang XC.
    Thorac Cancer; 2020 Feb 23; 11(2):346-352. PubMed ID: 31794146
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.